证券代码：600332 证券简称：白云山 公告编号：2025-085 广州白云山医药集团股份有限公司 关于召开2025年第三次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东会类型和届次 2025年第三次临时股东会 股东会召开日期：2025年12月30日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 股东会股权登记日: 2025年12月22日 股东会召开地点:中国广东省广州市荔湾区沙面北街45号广州白云山医 药集团股份有限公司（"本公司"或"公司"）会议室 本公告仅适用于A股股东,H股股东登记及出席须知请参阅本公司于2025 年12月5日在香港联合交易所有限公司网站（https://www.hkexnews.h k/index_c.htm）刊发的"关于召开2025年第三次临时股东会的通告"。 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 (四) 现场会议召开的日期、时间和地点 ...

Group 1: Company Overview - HuiGu New Materials is focused on the polymer materials sector, particularly functional coating materials, with a strong emphasis on self-research and development [1][3] - The company has a diverse product portfolio that includes heat exchanger energy-saving coatings, metal packaging coatings, and coatings for new energy applications [5][6][7] - As of June 2025, HuiGu New Materials had 755 employees, with a significant portion dedicated to production and R&D [20] Group 2: Revenue and Client Concentration - Revenue from the home appliance sector accounts for approximately 40% of total income, while packaging contributes over 30%, indicating a high client concentration risk [2][4][8] - The top five clients accounted for 43.65% to 48.19% of sales during the reporting period, showing an increasing trend in client concentration [8] - The company's main business revenue totaled approximately 49.23 million in the first half of 2025, with a gross profit margin of 45.16% [12][13] Group 3: Financial Performance - HuiGu New Materials reported revenues of approximately 664 million, 717 million, 817 million, and 496 million for the years 2022, 2023, 2024, and the first half of 2025, respectively [12] - The net profit for the same periods was approximately 26 million, 106 million, 146 million, and 107 million [12] - The company has experienced a growth trend in performance due to an increase in high-margin product sales and a decrease in raw material prices [10] Group 4: Market Position and Industry Outlook - The industrial coating market in China is projected to exceed 270 billion by 2024, with an expected annual growth rate of 13% from 2024 to 2029 [15] - HuiGu New Materials has achieved a domestic market share of over 60% in heat exchanger coatings and over 30% in metal packaging coatings, indicating a strong competitive position [18] - The company is positioned to benefit from domestic localization and import substitution trends in the functional coating materials industry [23] Group 5: IPO and Future Plans - HuiGu New Materials plans to raise 900 million through its IPO to fund expansion projects and working capital [23] - The company has a history of cash dividends, with amounts distributed in recent years being 17.5 million, 15 million, 15.15 million, and 34.56 million [22] - The IPO is seen as a critical step for the company to enhance its production capacity and R&D capabilities [23]

2025年第三次臨時股東會授權委託書 與本授權委託書有關之 股份數目 （附註1） 本人╱吾等 （附註2） 單位（個人）出席廣州白雲山醫藥集團股份有限公司（「公司」或「本公司」）於2025年12月30日（星期二）上午十時在中華人民共和 國廣東省廣州市荔灣區沙面北街45號舉行本公司之2025年第三次臨時股東會（包括其續會）（「臨時股東會」），並代為行使表 決權，以及根據法規及公司的公司章程細則行使委任代表所獲賦予的一切權利，藉以代表本人╱吾等以本人╱吾等名義， 按下列指示考慮並酌情通過臨時股東會通告所載之決議案： | | 普通決議案 | 贊成 | （附註4） | 反對 | （附註4） | 棄權 | （附註4） | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. | 關於廣州醫藥股份有限公司開展應收賬款資產證券化業務的議 | | | | | | | | | 案 | | | | | | | | 2. | 關於募集資金投資項目結項及節餘募集資金永久補充流動資金 | | | | | | | | | 的議案 | | | | | | | 委託人簽名 （附註5） ： ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 關於召開2025年第三次臨時股東會的通告 重要內容提示 一、召開臨時股東會基本情況 （一）召開臨時股東會 本公司第九屆董事會（「董事會」）第三十一次會議審議並通過關於召開臨時股東會的議案。 （二）臨時股東會日期和時間 本次臨時股東會將於2025年12月30日（星期二）上午10:00召開。 （三）臨時股東會現場會議召開地點 本次臨時股東會將於中國廣東省廣州市荔灣區沙面北街45號本公司會議室召開。 （四）會議召集人 本次臨時股東會的會議召集人為董事會。 2 1. 關於廣州醫藥股份有限公司開展應收賬款資產證券化業務的議案； 2. 關於募集資金投資項目結項及節餘募集資金永久補充流動資金的議案。 四、其他事項 1 • 2025年第三次臨時股東會（「臨時股東會」）召開日期及時間：2025年12月30日（星期二）上午10:00 • 臨時股東會召開地點：中華人民共和國（「中國」）廣東省廣州市荔灣區沙面北街45號廣州白雲 ...

此乃要件 請即處理 如 閣下對本通函的任何地方或應採取的行動有任何疑問，應諮詢 閣下的持牌證券 交易商或註冊證券機構、銀行經理、律師、專業會計師或其他專業顧問。 如 閣下已售出或轉讓名下全部本公司的股份，應立即將本通函連同授權委託書送交 買主或承讓人或經手買賣或轉讓之銀行、持牌證券交易商、註冊證券機構或其他代理 商，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部份 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 (1)建議廣州醫藥開展應收賬款資產證券化業務； (2)建議將募集資金投資項目結項並將節餘募集資金永久補充流動資金； 及 (3)臨時股東會通告 本封面頁所用詞彙與本通函內所界定者具有相同涵義。 董事會函件載於本通函第3頁至第11頁。本公司謹定於2025年12月30日（星期二）上午10 時正假座中國廣東省廣州市荔灣區沙面北街45號本公司會議室舉行臨時股東會。臨時 股東會之通告載於本通函的第12頁至第14頁。 無論 閣下是否打算出席臨時股東會， 閣下均須盡快根據隨上述通告附 ...

Core Insights - The North Border Craftsman Training Camp serves as both a skills enhancement program and a spiritual awakening, emphasizing the importance of craftsmanship and dedication to manufacturing [1] - The training camp aims to elevate the skills and innovative perspectives of over 40 craftsmen from key industries in Inner Mongolia through immersive learning experiences [1][3] Group 1: Training Program Structure - The training camp focuses on five core capabilities of craftsmanship: leadership, inheritance, focus, achievement, and innovation, transforming abstract concepts into practical applications through site visits and interactive exchanges [3] - Participants engage with industry leaders and technical experts from prominent companies such as Guangzhou Pharmaceutical Group and GAC Group, enhancing their understanding of advanced technologies and practices [5] Group 2: Outcomes and Future Directions - The training camp is aligned with the spirit of the 20th National Congress of the Communist Party, guiding craftsmen to contribute to high-quality development in their respective industries [7][8] - The initiative represents a new approach to talent cultivation, fostering collaboration and communication across regions, ultimately aiming to build a high-quality workforce in Inner Mongolia [8]

Core Insights - The establishment of the Hainai Global R&D Center in Guangzhou marks a significant shift in the skincare industry from marketing-driven competition to research-driven competition [1][4] - Over the past three years, leading companies in China's skincare industry have increased their R&D investment from 3%-4% to 6%-10% of revenue, indicating a trend towards enhancing research capabilities [1] - The center aims to create a comprehensive R&D system that links local research with international resources, featuring nine functional laboratories [1][3] Industry Trends - The competition in the skincare sector is now focused on "research direction," "research depth," and "research conversion capability," which are essential for brands to succeed [2] - The growth of Chinese skincare brands will be driven by research, and their brand strength will increasingly depend on their research capabilities [4] - The opening of the Hainai Global R&D Center symbolizes a critical step for domestic brands to compete on a global stage, narrowing the gap with international brands that have historically relied on established R&D systems and patent matrices [4] Research Strategy - Hainai's R&D strategy includes a dual hub system that integrates global and local research efforts, establishing a sustainable innovation engine [3] - The research depth is enhanced by a team led by Nobel laureate Konstantin Novoselov and a group of nearly 40 PhD-level researchers focusing on innovative ingredient research [3] - Hainai plans to leverage its various brands to implement the latest effective skincare research outcomes, creating practical and evidence-based products [3]

Group 1 - The Artemisinin concept index rose by 0.57%, ranking 6th among concept sectors, with six stocks increasing in value, including Delong Huineng, Haizheng Pharmaceutical, and China Resources Double Crane, which rose by 4.38%, 2.49%, and 0.75% respectively [1] - The stocks with the largest declines included Baihua Pharmaceutical, Rundu Co., and Fosun Pharmaceutical, which fell by 2.20%, 0.50%, and 0.15% respectively [1] Group 2 - The main capital flow analysis indicates that the Artemisinin concept sector experienced a net outflow of 73 million yuan, with three stocks receiving net inflows, led by Haizheng Pharmaceutical with a net inflow of 2.9933 million yuan [2] - Other stocks with notable net inflows include Fosun Pharmaceutical and Kunming Pharmaceutical Group, with net inflows of 1.7788 million yuan and 1.4040 million yuan respectively [2] Group 3 - In terms of capital inflow ratios, Kunming Pharmaceutical Group, Haizheng Pharmaceutical, and Fosun Pharmaceutical had the highest net inflow rates at 3.59%, 1.88%, and 0.82% respectively [3] - The capital flow data for the Artemisinin concept shows that Haizheng Pharmaceutical had a daily increase of 2.49% with a turnover rate of 1.25% and a net inflow of 2.9933 million yuan [3] - Conversely, stocks like Rundu Co. and Zhejiang Medicine experienced negative net inflows of -2.35 million yuan and -3.5082 million yuan respectively, with net inflow rates of -4.49% and -5.28% [4]

Core Viewpoint - The A-share market continues to decline, with major indices experiencing losses, while the traditional Chinese medicine (TCM) ETFs show resilience and growth amid a recovering market sentiment in the TCM sector [1][2]. Market Performance - The Shanghai Composite Index fell by 0.51% to 3878 points, the Shenzhen Component Index dropped by 0.78%, and the ChiNext Index decreased by 1.12% [1]. - The total market turnover reached 1.68 trillion yuan, an increase of 763 billion yuan compared to the previous trading day, with over 3800 stocks declining [1]. TCM ETFs - TCM ETFs, including the TCM ETF, TCM ETF Huatai-PB, and TCM 50 ETF, experienced gains, with respective increases of 0.92%, 0.90%, and 0.81% [2]. - The TCM ETF tracks the CSI Traditional Chinese Medicine Index, with key stocks including Yunnan Baiyao, Pien Tze Huang, and Tong Ren Tang [1][2]. TCM Market Trends - The TCM market is showing signs of recovery, with increased market activity and positive investment sentiment [2]. - The TCM sector benefits from both pharmaceutical and consumer attributes, with a high dividend yield of 2.69% over the past 12 months, placing it in the 90.91% historical percentile since its inception [2]. Price Governance in TCM - Multiple regions in China have initiated price governance for traditional Chinese medicine, aiming to create a unified and competitive drug market [3][4]. - The focus is on high-priced TCM products with significant clinical usage, particularly those sold primarily in the outpatient market [4]. Industry Dynamics - The ongoing price governance and centralized procurement are expected to lead to price convergence between hospital and outpatient markets, reshaping competitive factors in the industry [4]. - Companies with unique products, strong clinical value, and effective cost control are likely to gain competitive advantages [4]. Investment Themes - Three main investment themes are identified: 1. Price governance, focusing on price reductions and market share for competitive products [5]. 2. Consumption recovery, driven by macroeconomic improvement and aging population, benefiting TCM sales [6]. 3. State-owned enterprise reform, which is expected to enhance performance and create investment opportunities [6]. Recommended Investment Targets - Companies with strong R&D capabilities, unique products, and those less affected by centralized procurement are recommended for investment [6]. - Emphasis is placed on TCM brands with strong market presence and those benefiting from state-owned enterprise reforms [6].

Group 1 - The Zhongzheng Traditional Chinese Medicine Index (930641) increased by 0.32%, with notable gains from companies such as Guangdong Wannianqing (301111) up 12.03%, and Panlong Pharmaceutical (002864) up 5.35% [1] - The demand for new therapies such as peptides, ADCs, small nucleic acids, and CGT is expected to remain high, with a recovery in outsourcing demand anticipated due to the overseas interest rate cut cycle [1] - The adjustment of the basic drug catalog is expected to continue, presenting opportunities for the adjustment of traditional Chinese medicine varieties [1] Group 2 - The Zhongzheng Traditional Chinese Medicine Index includes companies involved in the production and sales of traditional Chinese medicine, reflecting the overall performance of the sector [2] - As of November 28, 2025, the top ten weighted stocks in the Zhongzheng Traditional Chinese Medicine Index accounted for 54.79% of the index, with notable companies including Yunnan Baiyao (000538) and Pianzaihuang (600436) [2]